Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

Coping behaviors and depressive status in individuals with type 2 diabetes mellitus.

Yasui-Furukori N, Murakami H, Otaka H, Nakayama H, Murabayashi M, Mizushiri S, Matsumura K, Tanabe J, Matsuhashi Y, Yanagimachi M, Nakamura K, Daimon M, Sugawara N.

Ann Gen Psychiatry. 2019 Jul 17;18:11. doi: 10.1186/s12991-019-0235-5. eCollection 2019.

2.

8-Hydroxylation and Glucuronidation of Mirtazapine in Japanese Psychiatric Patients: Significance of the Glucuronidation Pathway of 8-Hydroxy-Mirtazapine.

Shinozaki M, Pierce J, Hayashi Y, Watanabe T, Sasaki T, Komahashi-Sasaki H, Akiyama K, Kato K, Inoue Y, Tsuchimine S, Yasui-Furukori N, Ozeki Y, Shimoda K.

Pharmacopsychiatry. 2019 Sep;52(5):237-244. doi: 10.1055/a-0918-6408. Epub 2019 Jun 3.

PMID:
31158907
3.

Personality associated with depressive status in individuals with type 2 diabetes mellitus.

Yasui-Furukori N, Murakami H, Otaka H, Nakayama H, Murabayashi M, Mizushiri S, Matsumura K, Tanabe J, Matsuhashi Y, Yanagimachi M, Nakamura K, Daimon M, Sugawara N.

Neuropsychiatr Dis Treat. 2019 May 3;15:1133-1139. doi: 10.2147/NDT.S200012. eCollection 2019.

4.

Competence to Consent and Its Relationship With Cognitive Function in Patients With Schizophrenia.

Sugawara N, Yasui-Furukori N, Sumiyoshi T.

Front Psychiatry. 2019 Apr 12;10:195. doi: 10.3389/fpsyt.2019.00195. eCollection 2019. Review.

5.

Insulinoma resembling a rapid eye movement sleep behavior disorder: a case report.

Kishi K, Kubo K, Tomita T, Nakamura K, Yasui-Furukori N.

Int Med Case Rep J. 2019 Feb 21;12:51-54. doi: 10.2147/IMCRJ.S200489. eCollection 2019.

6.

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan.

Sugawara N, Kudo S, Ishioka M, Sato Y, Kubo K, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2019 Jan 9;15:205-211. doi: 10.2147/NDT.S188337. eCollection 2019.

7.

Differences in etiological beliefs about schizophrenia among patients, family, and medical staff.

Tarakita N, Yoshida K, Sugawara N, Kubo K, Furukori H, Fujii A, Nakamura K, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2018 Dec 27;15:137-142. doi: 10.2147/NDT.S185483. eCollection 2019.

8.

Effects of personality on the association between paroxetine plasma concentration and response.

Tomita T, Yasui-Furukori N, Nakagami T, Tsuchimine S, Ishioka M, Kaneda A, Nakamura K.

Neuropsychiatr Dis Treat. 2018 Nov 29;14:3299-3306. doi: 10.2147/NDT.S187060. eCollection 2018.

9.

Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.

Kumagai F, Suzuki T, Fleischhacker WW, Yasui-Furukori N, Mimura M, Uchida H.

J Clin Psychiatry. 2018 Dec 4;80(1). pii: 18m12144. doi: 10.4088/JCP.18m12144.

PMID:
30549487
10.

Suvorexant-Induced Delirium.

Yoshida K, Nakamura K, Yasui-Furukori N.

Prim Care Companion CNS Disord. 2018 Nov 15;20(6). pii: 18l02297. doi: 10.4088/PCC.18l02297. No abstract available.

11.

Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.

Akamine Y, Yasui-Furukori N, Uno T.

Curr Drug Metab. 2019;20(2):124-129. doi: 10.2174/1389200219666181003142036. Review.

PMID:
30280663
12.

Higher plasma leptin and lower C-peptide levels are associated with depression: A cross-sectional study.

Takekawa D, Kudo T, Saito J, Kimura F, Nikaido Y, Sawada K, Yasui-Furukori N, Hirota K.

J Affect Disord. 2019 Jan 15;243:70-74. doi: 10.1016/j.jad.2018.09.014. Epub 2018 Sep 11.

PMID:
30236760
13.

Tandospirone-Induced Rhabdomyolysis.

Miyazaki K, Otaka M, Yasui-Furukori N.

Clin Neuropharmacol. 2018 Nov/Dec;41(6):216-217. doi: 10.1097/WNF.0000000000000303.

PMID:
30204599
14.

Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs.

Kubo K, Fleischhacker WW, Suzuki T, Yasui-Furukori N, Mimura M, Uchida H.

Acta Psychiatr Scand. 2019 Feb;139(2):108-116. doi: 10.1111/acps.12960. Epub 2018 Sep 9.

PMID:
30198163
15.

Association between insomnia and personality traits among Japanese patients with type 2 diabetes mellitus.

Otaka H, Murakami H, Nakayama H, Murabayashi M, Mizushiri S, Matsumura K, Tanabe J, Matsuhashi Y, Yanagimachi M, Yoshida K, Sugawara N, Yasui-Furukori N, Daimon M.

J Diabetes Investig. 2019 Mar;10(2):484-490. doi: 10.1111/jdi.12927. Epub 2018 Oct 24.

16.

Association between insomnia and coping style in Japanese patients with type 2 diabetes mellitus.

Yoshida K, Otaka H, Murakami H, Nakayama H, Murabayashi M, Mizushiri S, Matsumura K, Tanabe J, Matsuhashi Y, Yanagimachi M, Sugawara N, Nakamura K, Daimon M, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2018 Jul 10;14:1803-1809. doi: 10.2147/NDT.S168934. eCollection 2018.

17.

High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.

Ono S, Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, Matsuda H, Sugawara N, Yasui-Furukori N, Okamoto K, Sagae T, Someya T.

BMC Psychiatry. 2018 Jun 8;18(1):180. doi: 10.1186/s12888-018-1764-1.

18.

The characteristics of understanding of depression among older patients treated with antidepressants: a comparison between older and younger patients.

Tomita T, Kudo S, Sugawara N, Fujii A, Tsuruga K, Sato Y, Ishioka M, Nakamura K, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2018 May 22;14:1319-1327. doi: 10.2147/NDT.S158254. eCollection 2018.

19.

Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.

Tsuchimine S, Ochi S, Tajiri M, Suzuki Y, Sugawara N, Inoue Y, Yasui-Furukori N.

Ther Drug Monit. 2018 Jun;40(3):356-361. doi: 10.1097/FTD.0000000000000506.

20.

Timing of psychoeducation for patients with depression who were treated with antidepressants: when should patients receive psychoeducation.

Tomita T, Kudo S, Sugawara N, Fujii A, Tsuruga K, Sato Y, Ishioka M, Nakamura K, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2018 Feb 12;14:505-510. doi: 10.2147/NDT.S156797. eCollection 2018.

21.

Increased levels of CREB in major depressive patients with antidepressant treatment.

Tsuchimine S, Sugawara N, Yasui-Furukori N.

Psychiatry Res. 2018 May;263:296-297. doi: 10.1016/j.psychres.2017.12.077. Epub 2018 Jan 2. No abstract available.

PMID:
29310886
22.

The Association Between the Severity and Level of Understanding of Depression Among Patients Treated With Antidepressants: A Survey of 424 Outpatients in Japan.

Tomita T, Yasui-Furukori N, Kudo S, Sugawara N, Fujii A, Tsuruga K, Sato Y, Ishioka M, Nakamura K.

Clin Neuropharmacol. 2018 Jan/Feb;41(1):1-5. doi: 10.1097/WNF.0000000000000257.

PMID:
29300204
23.

Irritable bowel syndrome and quality of life in a community-dwelling population in Japan.

Sugawara N, Sato K, Takahashi I, Satake R, Fukuda S, Nakaji S, Yasui-Furukori N.

Int J Psychiatry Med. 2018 May;53(3):159-170. doi: 10.1177/0091217417749791. Epub 2017 Dec 27.

PMID:
29280689
24.

Delirium in hemodialysis predicts mortality: a single-center, long-term observational study.

Yasui-Furukori N, Tarakita N, Uematsu W, Saito H, Nakamura K, Ohyama C, Sugawara N.

Neuropsychiatr Dis Treat. 2017 Dec 14;13:3011-3016. doi: 10.2147/NDT.S152355. eCollection 2017.

25.

Effects of nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan: A randomized controlled trial.

Sugawara N, Sagae T, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, Matsuda H, Suzuki Y, Ozeki Y, Okamoto K, Someya T.

J Psychiatr Res. 2018 Feb;97:77-83. doi: 10.1016/j.jpsychires.2017.12.002. Epub 2017 Dec 5.

PMID:
29220825
26.

Prevalence of underweight in patients with schizophrenia: A meta-analysis.

Sugawara N, Maruo K, Sugai T, Suzuki Y, Ozeki Y, Shimoda K, Someya T, Yasui-Furukori N.

Schizophr Res. 2018 May;195:67-73. doi: 10.1016/j.schres.2017.10.017. Epub 2017 Oct 17. Review.

PMID:
29054486
27.

Application of a stratum-specific likelihood ratio analysis in a screen for depression among a community-dwelling population in Japan.

Sugawara N, Kaneda A, Takahashi I, Nakaji S, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2017 Sep 12;13:2369-2374. doi: 10.2147/NDT.S142517. eCollection 2017.

28.

Attitudes toward placebo-controlled clinical trials among depressed patients in Japan.

Sugawara N, Ishioka M, Tsuchimine S, Tsuruga K, Sato Y, Tarakita N, Furukori H, Kudo S, Tomita T, Nakagami T, Yasui-Furukori N.

J Affect Disord. 2018 Jan 1;225:313-316. doi: 10.1016/j.jad.2017.08.061. Epub 2017 Aug 31.

PMID:
28843082
29.

Levodopa-responsive depression associated with corticobasal degeneration: a case report.

Tarakita N, Nishijima H, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2017 Apr 18;13:1107-1110. doi: 10.2147/NDT.S136706. eCollection 2017.

30.

Work-family conflict as a mediator between occupational stress and psychological health among mental health nurses in Japan.

Sugawara N, Danjo K, Furukori H, Sato Y, Tomita T, Fujii A, Nakagami T, Kitaoka K, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2017 Mar 13;13:779-784. doi: 10.2147/NDT.S127053. eCollection 2017.

31.

Bipolar disorder recurrence prevention using self-monitoring daily mood charts: case reports from a 5 year period.

Yasui-Furukori N, Nakamura K.

Neuropsychiatr Dis Treat. 2017 Mar 7;13:733-736. doi: 10.2147/NDT.S132355. eCollection 2017.

32.

Depressive Symptoms and Coping Behaviors among Individuals with Irritable Bowel Syndrome in Japan.

Sugawara N, Sato K, Takahashi I, Satake R, Fukuda S, Nakaji S, Yasui-Furukori N.

Intern Med. 2017;56(5):493-498. doi: 10.2169/internalmedicine.56.7695. Epub 2017 Mar 1.

33.

Cardiac sarcoidosis resembling panic disorder: a case report.

Tokumitsu K, Demachi J, Yamanoi Y, Oyama S, Takeuchi J, Yachimori K, Yasui-Furukori N.

BMC Psychiatry. 2017 Jan 13;17(1):14. doi: 10.1186/s12888-016-1184-z.

34.

High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey.

Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, Matsuda H, Sugawara N, Yasui-Furukori N, Minami Y, Okamoto K, Sagae T, Someya T.

PLoS One. 2016 Nov 17;11(11):e0166429. doi: 10.1371/journal.pone.0166429. eCollection 2016.

35.

Prevalence of major depressive disorder among hemodialysis patients compared with healthy people in Japan using the Structured Clinical Interview for DSM-IV.

Tomita T, Yasui-Furukori N, Sugawara N, Ogasawara K, Katagai K, Saito H, Sawada K, Takahashi I, Nakamura K.

Neuropsychiatr Dis Treat. 2016 Sep 30;12:2503-2508. eCollection 2016.

36.

Insomnia in patients on hemodialysis for a short versus long duration.

Tomita T, Yasui-Furukori N, Oka M, Shimizu T, Nagashima A, Mitsuhashi K, Saito H, Nakamura K.

Neuropsychiatr Dis Treat. 2016 Sep 2;12:2293-8. doi: 10.2147/NDT.S106819. eCollection 2016.

37.

The Effect of Yokukansan, a Traditional Herbal Preparation Used for the Behavioral and Psychological Symptoms of Dementia, on the Drug-Metabolizing Enzyme Activities in Healthy Male Volunteers.

Soraoka H, Oniki K, Matsuda K, Ono T, Taharazako K, Uchiyashiki Y, Kamihashi R, Kita A, Takashima A, Nakagawa K, Yasui-Furukori N, Kadowaki D, Miyata K, Saruwatari J.

Biol Pharm Bull. 2016;39(9):1468-74. doi: 10.1248/bpb.b16-00248.

38.

An attempt to construct a 7-item short version of the temperament and character inventory to predict the treatment response of patients with depression; a validation study.

Tomita T, Yasui-Furukori N, Kaneda A, Ishioka M, Sugawara N, Nakagami T, Nakamura K.

BMC Psychiatry. 2016 Aug 12;16:290. doi: 10.1186/s12888-016-0997-0.

39.

Serum x03C9;-3 and x03C9;-6 Fatty Acids Are Not Associated with Personality Traits in Healthy Japanese Young People.

Tsuchimine S, Kaneda A, Yasui-Furukori N.

Neuropsychobiology. 2016;73(4):249-53. doi: 10.1159/000446920. Epub 2016 Jul 8.

PMID:
27388608
40.

Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.

Nishimura M, Ueda M, Saruwatari J, Nakashima H, Ogusu N, Aoki A, Tsuchimine S, Matsuda K, Iwashita K, Ono T, Oniki K, Shimoda K, Yasui-Furukori N.

Pharmacogenet Genomics. 2016 Sep;26(9):403-13. doi: 10.1097/FPC.0000000000000228.

PMID:
27187662
41.

Items of the Montgomery-├ůsberg Depression Rating Scale Associated With Response to Paroxetine Treatment in Patients With Major Depressive Disorder.

Tomita T, Sato Y, Nakagami T, Tsuchimine S, Kaneda A, Kaneko S, Nakamura K, Yasui-Furukori N.

Clin Neuropharmacol. 2016 May-Jun;39(3):135-9. doi: 10.1097/WNF.0000000000000146.

PMID:
27171569
42.

Characteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study.

Yasui-Furukori N, Hashimoto K, Tsuchimine S, Tomita T, Sugawara N, Ishioka M, Nakamura K.

Clin Neuropharmacol. 2016 May-Jun;39(3):125-7. doi: 10.1097/WNF.0000000000000139.

PMID:
27171568
43.

Relationship between quality of life and restless legs syndrome among a community-dwelling population in Japan.

Kubo K, Sugawara N, Kaneda A, Takahashi I, Nakamura K, Nakaji S, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2016 Apr 12;12:809-15. doi: 10.2147/NDT.S102089. eCollection 2016.

44.

Relationship between the lesion location of acute ischemic stroke and early depressive symptoms in Japanese patients.

Metoki N, Sugawara N, Hagii J, Saito S, Shiroto H, Tomita T, Yasujima M, Okumura K, Yasui-Furukori N.

Ann Gen Psychiatry. 2016 Apr 1;15:12. doi: 10.1186/s12991-016-0099-x. eCollection 2016.

45.

Glutathione S-transferase K1 genotype and overweight status in schizophrenia patients: A pilot study.

Oniki K, Kamihashi R, Tomita T, Ishioka M, Yoshimori Y, Osaki N, Tsuchimine S, Sugawara N, Kajiwara A, Morita K, Miyata K, Otake K, Nakagawa K, Ogata Y, Saruwatari J, Yasui-Furukori N.

Psychiatry Res. 2016 May 30;239:190-5. doi: 10.1016/j.psychres.2016.03.025. Epub 2016 Mar 16.

PMID:
27010189
46.

The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients.

Yasui-Furukori N, Tsuchimine S, Kubo K, Ishioka M, Nakamura K, Inoue Y.

Ther Drug Monit. 2016 Aug;38(4):483-6. doi: 10.1097/FTD.0000000000000303.

PMID:
27002781
47.

Attitudes toward metabolic adverse events among patients with schizophrenia in Japan.

Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, Matsuda H, Suzuki Y, Minami Y, Ozeki Y, Okamoto K, Sagae T, Someya T.

Neuropsychiatr Dis Treat. 2016 Feb 24;12:427-36. doi: 10.2147/NDT.S98711. eCollection 2016.

48.

Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia: A nationwide survey.

Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, Matsuda H, Sugawara N, Yasui-Furukori N, Minami Y, Okamoto K, Sagae T, Someya T.

Schizophr Res. 2016 Mar;171(1-3):68-73. doi: 10.1016/j.schres.2016.01.016. Epub 2016 Jan 22.

PMID:
26811231
49.

[The Drug Interaction that Psychiatrists Should be Careful about].

Yasui-Furukori N.

Seishin Shinkeigaku Zasshi. 2016;118(3):152-158. Japanese.

PMID:
30620511
50.

Prevalence and Predictive Factors of Irritable Bowel Syndrome in a Community-dwelling Population in Japan.

Satake R, Sugawara N, Sato K, Takahashi I, Nakaji S, Yasui-Furukori N, Fukuda S.

Intern Med. 2015;54(24):3105-12. doi: 10.2169/internalmedicine.54.5378. Epub 2015 Dec 15.

Supplemental Content

Loading ...
Support Center